Compass Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CMPX Nasdaq 2836 www.compasstherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Compass Therapeutics, Inc.

Compass Therapeutics to Participate in Upcoming June Investor Events - May 28th, 2026 5:30 am
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting - May 21st, 2026 3:00 pm
Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M - May 17th, 2026 10:50 pm
Compass Therapeutics to Participate in Upcoming May Investor Events - May 12th, 2026 5:30 am
Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX) - May 5th, 2026 6:16 am
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update - May 5th, 2026 5:30 am
Does Compass Therapeutics' (CMPX) Biliary Cancer Data Hint At A Broader Pipeline Re‑Rating Opportunity? - Apr 29th, 2026 5:04 am
Micron initiated, Rambus downgraded: Wall Street's top analyst calls - Apr 28th, 2026 8:19 am
Compass Therapeutics’s stock crashes after OS miss in BTC trial - Apr 28th, 2026 5:21 am
Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARC - Apr 27th, 2026 6:01 pm
Compass Therapeutics Touts “Stunning” PFS Win in COMPANION-002 as Crossover Muddy OS Data - Apr 27th, 2026 2:42 pm
This Biotech Stock Is Down 65%. How a Cancer Trial Was Ruined by Its Own Design. - Apr 27th, 2026 1:19 pm
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer - Apr 27th, 2026 5:30 am
Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Path To Profitability - Apr 26th, 2026 6:28 am
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer - Apr 24th, 2026 2:00 pm
Compass Therapeutics, Inc. (CMPX) Up 200% Year-on-Year - Apr 21st, 2026 3:16 pm
Will Psychedelic Stocks Have A Trippy Ride Under RFK Jr.? - Apr 2nd, 2026 9:31 am
What Compass Therapeutics (CMPX)'s Pipeline Progress And 2025 Losses Reveal About Its Oncology Strategy - Mar 9th, 2026 3:08 am
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update - Mar 5th, 2026 5:30 am
Assessing Compass Therapeutics (CMPX) Valuation As CTX-009 Gains Attention In Biliary Tract Cancer Market - Mar 3rd, 2026 2:21 am